A Phase 2 interventional study of Clopidogrel and Placebo in Asthma, sponsored by University of Southampton. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2023-05-22.
Sponsored by University of Southampton · Phase 2, Interventional, and Basic science
In asthma, breathing in an allergen, such as house dust mite induces inflammation in the airways. This process appears to involve an interaction between two different sorts of blood cells, platelets and white blood cells via a receptor called the P2Y12 receptor. The purpose of this study is to determine whether the drug clopidogrel which blocks the P2Y12 receptor on platelets, reduces inflammation following breathing in house dust mite in people with mild asthma.
3,921 studies on the registry are indexed under Asthma; 507 are open to participants now.
This study's planned enrollment of 24 is below the median of 83 across 2,752 interventional studies indexed under Asthma.
Browse Asthma studies →University of Southampton is the lead sponsor of 121 studies on the registry; 19 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Arm given placebo
Drug: Placebo
Group given clopidogrel
Drug: Clopidogrel
Clopidogrel 75mg daily for 7 days
Matched placebo
Change in sputum eosinophils following allergen challenge in the presence and absence of clopiodgorel
Time frame: 8 days
Provoking concentration of methacholine inducing 20% fall in forced expiratory volume in 1 second
Time frame: 8 days
Change in sputum tissue factor concentration following allergen challenge in the presence and absence of clopidogrel
Time frame: 8 days
Change in sputum tissue factor inhibitor concentration following allergen challenge in the presence and absence of clopidogrel
Time frame: 8 days
Change in sputum thrombin activatable finbrinolysis inhibitor concentration following allergen challenge in the presence and absence of clopidogrel
Time frame: 8 days
Change in sputum P-selectin concentration following allergen challenge in the presence and absence of clopidogrel
Time frame: 8 days
Change in peripheral blood eosinophil and platelet counts following allergen challenge in the presence and absence of clopidogrel
Time frame: 8 days
Change in urine fibrin degradation products and leukotriene E4 following allergen challenge in the presence and absence of clopidogrel
Time frame: 8 days
This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Southampton